

Rita Nanda

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/118709/publications.pdf>

Version: 2024-02-01

85
papers

9,779
citations

81743

39
h-index

62479

80
g-index

89
all docs

89
docs citations

89
times ranked

11941
citing authors

#	ARTICLE	IF	CITATIONS
1	Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 2460-2467.	0.8	1,185
2	The molecular portraits of breast tumors are conserved across microarray platforms. <i>BMC Genomics</i> , 2006, 7, 96.	1.2	1,169
3	Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. <i>Modern Pathology</i> , 2006, 19, 264-271.	2.9	932
4	Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer. <i>JAMA Oncology</i> , 2019, 5, 74.	3.4	557
5	Adaptive Randomization of Veliparibâ€“Carboplatin Treatment in Breast Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 23-34.	13.9	467
6	Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer. <i>JAMA Oncology</i> , 2020, 6, 676.	3.4	419
7	Enzalutamide for the Treatment of Androgen Receptorâ€“Expressing Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 884-890.	0.8	365
8	Population Differences in Breast Cancer: Survey in Indigenous African Women Reveals Over-Representation of Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 4515-4521.	0.8	341
9	Adaptive Randomization of Neratinib in Early Breast Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 11-22.	13.9	301
10	TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. <i>Journal of Clinical Oncology</i> , 2020, 38, 4274-4282.	0.8	276
11	Multicenter Phase II Study of Neoadjuvant Lapatinib and Trastuzumab With Hormonal Therapy and Without Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 2â€“Overexpressing Breast Cancer: TBCRC 006. <i>Journal of Clinical Oncology</i> , 2013, 31, 1726-1731.	0.8	238
12	A Genome-Wide Screen for Promoter Methylation in Lung Cancer Identifies Novel Methylation Markers for Multiple Malignancies. <i>PLoS Medicine</i> , 2006, 3, e486.	3.9	228
13	Genetic Testing in an Ethnically Diverse Cohort of High-Risk Women. <i>JAMA - Journal of the American Medical Association</i> , 2005, 294, 1925.	3.8	219
14	BRCA1 Promoter Methylation in Sporadic Breast Cancer Is Associated with Reduced BRCA1 Copy Number and Chromosome 17 Aneusomy. <i>Cancer Research</i> , 2005, 65, 10692-10699.	0.4	170
15	Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. <i>Cancer</i> , 2013, 119, 1776-1783.	2.0	166
16	Advances in Breast Cancer: Pathways to Personalized Medicine. <i>Clinical Cancer Research</i> , 2008, 14, 7988-7999.	3.2	165
17	Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer. <i>JAMA Oncology</i> , 2020, 6, 1410.	3.4	161
18	Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2.. <i>Journal of Clinical Oncology</i> , 2017, 35, 506-506.	0.8	160

#	ARTICLE	IF	CITATIONS
19	Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial. <i>Cancer Cell</i> , 2021, 39, 989-998.e5.	7.7	131
20	Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer. <i>JAMA Oncology</i> , 2020, 6, 1355.	3.4	119
21	The impact of site-specific digital histology signatures on deep learning model accuracy and bias. <i>Nature Communications</i> , 2021, 12, 4423.	5.8	111
22	Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A.. <i>Journal of Clinical Oncology</i> , 2017, 35, 1008-1008.	0.8	99
23	TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR+ Metastatic Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 2111-2123.	3.2	91
24	Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline <i>BRCA1</i> or <i>BRCA2</i> -Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083. <i>Clinical Cancer Research</i> , 2017, 23, 4066-4076.	3.2	87
25	Estrogen receptor \pm , <i>BRCA1</i> , and <i>FANCF</i> promoter methylation occur in distinct subsets of sporadic breast cancers. <i>Breast Cancer Research and Treatment</i> , 2008, 111, 113-120.	1.1	82
26	Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019. <i>Clinical Cancer Research</i> , 2015, 21, 2771-2779.	3.2	78
27	The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 2911-2915.	3.2	77
28	Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 2375-2385.	0.8	76
29	Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 167, 731-740.	1.1	71
30	Immune Checkpoint Blockade for Breast Cancer. <i>Cancer Treatment and Research</i> , 2018, 173, 155-165.	0.2	69
31	MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 1059-1069.	0.8	69
32	Atezolizumab for the treatment of breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 151-158.	1.1	60
33	TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases. <i>Breast Cancer Research and Treatment</i> , 2014, 146, 557-566.	1.1	59
34	TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 2722-2729.	3.2	57
35	Phase 2 study of pembrolizumab as first-line therapy for PD-L1-positive metastatic triple-negative breast cancer (mTNBC): Preliminary data from KEYNOTE-086 cohort B.. <i>Journal of Clinical Oncology</i> , 2017, 35, 1088-1088.	0.8	55
36	Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [¹⁸ F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003). <i>Journal of Clinical Oncology</i> , 2015, 33, 2623-2631.	0.8	49

#	ARTICLE	IF	CITATIONS
37	A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013, 139, 145-153.	1.1	48
38	Targeting the Human Epidermal Growth Factor Receptor 2 (HER2) in the Treatment of Breast Cancer: Recent Advances and Future Directions. <i>Reviews on Recent Clinical Trials</i> , 2007, 2, 111-116.	0.4	46
39	Treatment of leptomeningeal carcinomatosis: Current challenges and future opportunities. <i>Journal of Clinical Neuroscience</i> , 2015, 22, 632-637.	0.8	46
40	Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer. <i>JAMA Oncology</i> , 2021, 7, 1654.	3.4	42
41	LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 637-648.	1.1	40
42	TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 821-827.	3.2	40
43	Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2â€“Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptorâ€“Negative: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2021, 39, 3938-3958.	0.8	40
44	Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial. <i>Nature Communications</i> , 2021, 12, 6428.	5.8	36
45	Immune Checkpoint Inhibitor Therapy in Breast Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 1259-1268.	2.3	32
46	TBCRC-010: Phase I/II Study of Dasatinib in Combination with Zoledronic Acid for the Treatment of Breast Cancer Bone Metastasis. <i>Clinical Cancer Research</i> , 2016, 22, 5706-5712.	3.2	30
47	A randomized phase I trial of nanoparticle albumin-bound paclitaxel with or without mifepristone for advanced breast cancer. <i>SpringerPlus</i> , 2016, 5, 947.	1.2	29
48	Racial disparities in survival outcomes among breast cancer patients by molecular subtypes. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 841-849.	1.1	25
49	Concepts and targets in triple-negative breast cancer: recent results and clinical implications. <i>Therapeutic Advances in Medical Oncology</i> , 2016, 8, 351-359.	1.4	24
50	Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint. <i>Npj Breast Cancer</i> , 2018, 4, 26.	2.3	24
51	ARV-471, an estrogen receptor (ER) PROTACdegrader, combined with palbociclib in advanced ER+/human epidermal growth factor receptor 2â€“negative (HER2-) breast cancer: Phase 1b cohort (part C) of a phase 1/2 study.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS1120-TPS1120.	0.8	24
52	Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 5510-5518.	3.2	23
53	BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 345-355.	0.8	23
54	â€œTargetingâ€“Triple-Negative Breast Cancer: The Lessons Learned From BRCA1-Associated Breast Cancers. <i>Seminars in Oncology</i> , 2011, 38, 254-262.	0.8	19

#	ARTICLE	IF	CITATIONS
55	Clinical trials of immunotherapy in triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2022, 195, 1-15.	1.1	19
56	Abstract CT011: Evaluation of durvalumab in combination with olaparib and paclitaxel in high-risk HER2 negative stage II/III breast cancer: Results from the I-SPY 2 TRIAL. <i>Cancer Research</i> , 2020, 80, CT011-CT011.	0.4	18
57	The emerging role of immune checkpoint inhibitors for the treatment of breast cancer. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 531-548.	1.9	16
58	Analyzing the clinical actionability of germline pharmacogenomic findings in oncology. <i>Cancer</i> , 2018, 124, 3052-3065.	2.0	14
59	Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 131.	2.3	13
60	Surgical Patterns of Care in Patients with Invasive Breast Cancer Treated with Neoadjuvant Systemic Therapy and Breast Magnetic Resonance Imaging: Results of a Secondary Analysis of TBCRC 017. <i>Annals of Surgical Oncology</i> , 2015, 22, 75-81.	0.7	12
61	Patient-provider communications about pharmacogenomic results increase patient recall of medication changes. <i>Pharmacogenomics Journal</i> , 2019, 19, 528-537.	0.9	12
62	Implementation of pharmacogenomic testing in oncology care (PhOCus): study protocol of a pragmatic, randomized clinical trial. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592097411.	1.4	12
63	KEYLYNK-009: A phase II/III, open-label, randomized study of pembrolizumab (pembro) plus olaparib vs pembro plus chemotherapy after induction with first-line pembro plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS596-TPS596.	0.8	12
64	Outcomes in patients (pts) aged ≥65 years in the phase 3 ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 1011-1011.	0.8	9
65	Evaluation of intra-tumoral (IT) SD-101 and pembrolizumab (Pb) in combination with paclitaxel (P) followed by AC in high-risk HER2-negative (HER2-) stage II/III breast cancer: Results from the I-SPY 2 trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 508-508.	0.8	9
66	Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial. <i>Npj Breast Cancer</i> , 2022, 8, 18.	2.3	8
67	Trial in progress: A phase II open-label, randomized study of PARP inhibition (olaparib) either alone or in combination with anti-PD-L1 therapy (atezolizumab) in homologous DNA repair (HDR) deficient, locally advanced or metastatic non-HER2-positive breast cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS1102-TPS1102.	0.8	7
68	The ImPrint immune signature to identify patients with high-risk early breast cancer who may benefit from PD1 checkpoint inhibition in I-SPY2.. <i>Journal of Clinical Oncology</i> , 2022, 40, 514-514.	0.8	6
69	Independent validation of simbiosys tumorscope to predict response to neoadjuvant chemotherapy (NACT) in early breast cancer (EBC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 582-582.	0.8	4
70	Abstract P3-09-02: Evaluation of a novel agent plus standard neoadjuvant therapy in early stage, high-risk HER2 negative breast cancer: Results from the I-SPY 2 TRIAL. , 2020, , .		4
71	Utility of patient-derived lymphoblastoid cell lines as an <i>ex vivo</i> capecitabine sensitivity prediction model for breast cancer patients. <i>Oncotarget</i> , 2016, 7, 38359-38366.	0.8	4
72	Improved pathologic complete response rates for triple-negative breast cancer in the I-SPY2 Trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 591-591.	0.8	4

#	ARTICLE	IF	CITATIONS
73	Saci-IO HR+: Randomized phase II trial of sacituzumab govitecan (SG) +/- pembrolizumab in PD-L1+ hormone receptor-positive (HR+) / HER2- metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2021, 39, TPS1102-TPS1102.	0.8	3
74	Differences Between Ipsilateral and Contralateral Early Parenchymal Enhancement Kinetics Predict Response of Breast Cancer to Neoadjuvant Therapy. Academic Radiology, 2022, 29, 1469-1479.	1.3	3
75	Early and Severe Radiation Esophagitis Associated With Concurrent Sirolimus. Journal of Clinical Oncology, 2016, 34, e73-e75.	0.8	2
76	Trial in progress: A phase 1b/2 study of the PARP inhibitor niraparib in combination with trastuzumab in patients with metastatic HER2+ breast cancer (TBCRC 050).. Journal of Clinical Oncology, 2021, 39, TPS1098-TPS1098.	0.8	2
77	Phase 1 pilot study with dose expansion of chemotherapy in combination with CD40 agonist and Flt3 ligand in metastatic triple-negative breast cancer.. Journal of Clinical Oncology, 2022, 40, TPS1126-TPS1126.	0.8	2
78	A phase 3, randomized, open-label study of the anti-Globo H vaccine adagloxad simolenin/obi-821 in the adjuvant treatment of high-risk, early-stage, Globo H-positive triple-negative breast cancer.. Journal of Clinical Oncology, 2022, 40, TPS611-TPS611.	0.8	1
79	Molecular Profiling and Targeted Therapy for Triple-Negative Breast Cancer. , 2018, , 117-140.		0
80	Multi-center randomized study of pembrolizumab/carboplatin versus carboplatin alone in patients with chest wall disease from breast cancer: TBCRC 044.. Journal of Clinical Oncology, 2021, 39, TPS1111-TPS1111.	0.8	0
81	Validation of the RSclin risk calculator using the National Cancer Database (NCDB).. Journal of Clinical Oncology, 2021, 39, 549-549.	0.8	0
82	Immunotherapy Approaches to Breast Cancer. Current Breast Cancer Reports, 2017, 9, 227-235.	0.5	0
83	Abstract P1-08-21: Assessing the impact of treatment interruptions during neoadjuvant therapy in early stage breast cancer. Cancer Research, 2022, 82, P1-08-21-P1-08-21.	0.4	0
84	Abstract P5-13-34: A multi-modal biomarker of immunotherapy response. Cancer Research, 2022, 82, P5-13-34-P5-13-34.	0.4	0
85	Racial differences in interest and use of integrative medicine among patients with breast cancer.. Journal of Clinical Oncology, 2022, 40, 12101-12101.	0.8	0